Latest Breaking News On - Oncology consortium - Page 5 : comparemela.com

Form 6-K KAZIA THERAPEUTICS LTD For: Nov 15

Form 6-K KAZIA THERAPEUTICS LTD For: Nov 15
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

British columbiaChimerix incKazia therapeuticsSociety of neuroOncology consortiumKazia therapeutics limitedKazia announcesPacific pediatric neuro oncology consortiumCombination trial

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Priority review granted with PDUFA target action date of April 30, 2024BRISBANE, Calif., Oct. 30, 2023 Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to.

United statesJeremy benderLaura cooperOncology consortiumHead of communicationsExchange commissionDrug administrationEuropean commissionCompany on linkedinOne biopharmaceuticalsNew drug applicationPrescription drug user fee actPediatric disease priority review voucherPacific pediatric neuro oncology consortiumResponse asessmentNeuro oncology high grade glioma

Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30

Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSoult ukpyolsiSouth koreaIsrael generalCity ofUnited kingdomNew south walesNew zealandSan franciscoDana farber cancer instituteNorth carolinaHong kongMemorial sloan kettering cancer centerUniversity of utahDistrict of columbia

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

SYDNEY, Sept. 29, 2023 /PRNewswire/ Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce that data from an ongoing Phase II study of paxalisib, an.

United statesNew south walesBritish columbiaJane loweKazia therapeutics limitedChimerix incExchange commissionOncology consortiumPrnewswire kazia therapeutics limitedMeeting of the society for neuroKazia therapeuticsIr departmentSociety for neuroTherapeutics limitedPacific pediatric neuro oncology consortiumAnnual meeting

Day One Announces Updated FIREFLY-1 Data for Tovorafenib

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,.

United statesJeremy benderLaura cooperCompany on linkedinExchange commissionOncology consortiumDrug administrationHead of communicationsEuropean commissionOne biopharmaceuticalsNew drug applicationDay oneClinical study reportResponse assessmentNeuro oncology high grade gliomaPediatric neuro oncology low grade glioma